Logo Image
|Articles|April 14, 2015

Clinical Conductor Adds CTMS Features to Facilitate Dynamic Research

The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year.

The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year. 

This quarter, the development team has added unique features including:

· Budget snapshots for better financial management and negotiations with sponsors

· The ability for organizations to create multiple charge masters

· Protocol versioning – where organizations can create new versions of a protocol and more easily handle amendments that occur

All of these features help solve an existing problem in research where technology can sometimes be lacking: flexibility. Since research is continuously changing, researchers and managers need technology capable of providing the granular data they need to remain profitable and produce high quality clinical research.

 

Read the full release.

 

 

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more